

In the Claims:

1. (Currently amended) A method of treating androgen independent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2, ~~and~~ blocks ligand activation of an ErbB receptor substantially more effectively than humanized monoclonal antibody huMAb4D5-8 (HERCEPTIN[®]), and blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB12697) to ErbB2.

2. (Canceled).

3. (Original) The method of claim 1 wherein the antibody blocks TGF- α activation of mitogen-activated protein kinase (MAPK).

4. (Earlier presented) The method of claim 1 wherein the antibody blocks formation of an ErbB hetero-oligomer.

5. (Previously amended) The method of claim 1 wherein the antibody comprises monoclonal antibody 2C4 (ATCC HB12697) or a humanized form thereof that binds to the same epitope as the monoclonal antibody 2C4 (ATCC HB12697).

6. (Original) The method of claim 1 wherein the antibody is an antibody fragment.

7. (Original) The method of claim 6 wherein the antibody fragment is a Fab fragment.

8. (Original) The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.

9. (Original) The method of claim 6 wherein the antibody fragment is not conjugated with a cytotoxic agent.

10.-21. (Canceled)

22. (Currently amended) A method of treating androgen independent prostate cancer in a human comprising administering to the human a therapeutically effective amount of an antibody which binds ErbB2, blocks ligand activation of an ErbB receptor, blocks by 50% or greater binding of monoclonal antibody 2C4 (ATCC HB12697) to ErbB2, and blocks TGF- α activation of mitogen activated protein kinase (MAPK).

23. (Previously amended) The method of claim 22 wherein the antibody comprises monoclonal antibody 2C4 (ATCC HB12697) or a humanized form thereof that binds to the same epitope as the monoclonal antibody 2C4 (ATCC HB12697).

24. (Previously presented) The method of claim 22 wherein the antibody is an antibody fragment.

25. (Previously presented) The method of claim 24 wherein the antibody fragment is a Fab fragment.

26. (Previously presented) The method of claim 22 wherein the antibody fragment is not conjugated with a cytotoxic agent.

27. (Previously presented) The method of claim 24 wherein the antibody fragment is not conjugated with a cytotoxic agent.

28.-31. (Canceled)